A company in northern California developing a test for the early detection of colorectal cancer has received six patents for its product. Sunnyvale, California-based CellMax Life said Tuesday it was ...

SUNNYVALE, Calif. and ROSWELL, Ga., March 23, 2021 /PRNewswire/ -- CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, and Sebela ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--CellMax Life, the precision cancer testing company, announced today the immediate availability in India of the CellMax-DNA Genetic Cancer Risk Test, which examines ...

A study by CellMax Life found that the company's blood-based test was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy. By filtering out and counting ...

Data shows 92% sensitivity for colorectal cancer and 55% sensitivity for precancerous advanced adenomas at 91% specificity. Data to be presented at ASCO Gastrointestinal Cancers Symposium The data ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--CellMax Life, Inc. today announced $9M in series A-1 venture funding, and formally introduced itself as a precision cancer blood-testing company providing ...

SUNNYVALE, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- CellMax Life, a molecular diagnostics company, announced today that its FirstSight™ pre-cancer and cancer detection blood test has received ...

CellMax Life has earned $9 million in Series A-1 venture funding, bringing their total funding to $14 million. The company aims to “fundamentally transform cancer care,” it said, using its ...

SUNNYVALE, Calif., May 4, 2020 /PRNewswire-PRWeb/ -- CellMax Life, a diagnostics company with a proprietary technology to detect pre-cancer and cancer cells in the blood, today announced new positive ...

In “Round B” of funding for the biometrics startup, CellMax, the company was able to raise $2 million to further advance its proprietary VioMetric technology. This, after collecting $1.3 million in ...

CellMax Life Inc. is joining a race to ease the process of detecting colon cancer in its earliest and most treatable stages, raising $9 million in Series A-1 financing and introducing a blood-based ...

Patents cover entirety of sub-$200 test and platform, which isolates rare circulating tumor cells (CTCs) from one tube of blood CellMax Life, enabling early cancer detection and management with ...